Beneficial Impact of Apremilast on Palmoplantar Keratodermas
DOI:
https://doi.org/10.2340/00015555-3805Keywords:
palmoplantar keratodermas, apremilast, psoriasisAbstract
Abstract is missing (Short communication)
Downloads
References
Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol 2018; 17: 835-840.
Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2018; 32: 1173-1179.
DOI: https://doi.org/10.1111/jdv.14832
Bissonnette R, Haydey R, Rosoph LA, Lynde CW, Burhalo M, Fowler JF, et al. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol 2018; 32: 403-410.
DOI: https://doi.org/10.1111/jdv.14647
Okazaki S, Osawa R, Nakajima H, Nakajima K, Sano S. Favorable response to apremilast in a patient with refractory psoriasis verrucosa. J Dermatol 2019;46: 544-547.
DOI: https://doi.org/10.1111/1346-8138.14877
Hazini AR, Rongioletti F, Rebona A. Pityriasis rubra pilaris and vitiligo in Down's syndrome. Clin Exp Dermatol 1988; 13: 334-335.
DOI: https://doi.org/10.1111/j.1365-2230.1988.tb00716.x
Terasaki K, Kanekura T, Saruwatari H, Kanzaki T. Classical juvenile pityriasis rubra pilaris with Down synsrome. Clin Dermatol 2004; 29: 49-51.
DOI: https://doi.org/10.1111/j.1365-2230.2004.01449.x
Krase IZ, Cavanaugh K, Curiel-Lewandrowski C. Treatment of refractory pityriasis rubra pilaris with novel phosphodiesterase 4 (PDE4) inhibitor apremilast. JAMA Dermatol 2016; 152: 348-350.
DOI: https://doi.org/10.1001/jamadermatol.2015.3405
Cho M, Honda T, Ueshima C, Kataoka T, Otsuka A, Kabashima K. A case of pityriasis rubra pilaris treated successfully with the phosphodiesterase-4 inhibitor apremilast. Acta Derm Venereol 2018; 98: 975-976.
DOI: https://doi.org/10.2340/00015555-2995
Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 2017; 153: 304-308.
DOI: https://doi.org/10.1001/jamadermatol.2016.5384
Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N, Okamoto H. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blocade of interleukin-17A, but improved after blockade of interleukin 23. J Dermatol 2019; 46: 70-72.
DOI: https://doi.org/10.1111/1346-8138.14709
Paller AS. Profiling immune expression to consider repurposing therapeutics for the ichthyoses. J Invest Dermatol 2019; 139: 535-540.
DOI: https://doi.org/10.1016/j.jid.2018.08.027
Malik K, He H, Huynh TN, Tran G, Mueller K, Doytcheva K, et al. Ichthyosis molecular fingerprinting shows profound T H 17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol 2019; 143: 604-618.
DOI: https://doi.org/10.1016/j.jaci.2018.03.021
Haiges D, Fisher J, Horer S, Has C, Schempp CM. Biologic therapy targeting IL-17 ameliorates a case of congenital ichthyosiform cornification disorder. J Dtsh Dermatol Ges 2019; 17: 70-72.
DOI: https://doi.org/10.1111/ddg.13716
Kataoka S, Takaishi M, Nakajima K, Sato S. Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation J Dermatol Sci 2020; 100: 230-233.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Kimiko Nakajima, Riho Nakajima, Hiroyuki Morisaka, Hideki Nakajima, Shigetoshi Sano
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
